Bloomberg Law
Aug. 14, 2019, 11:00 AM

Gilead’s New Drug Descovy Spotlights Old Cracks in HIV Care

Elliott T. Dube
Elliott T. Dube

Researchers started noticing in the early 1980s that gay men seemed most susceptible to the virus that causes AIDS. Nearly four decades later, women made up 19% of new HIV diagnoses in the U.S., but clinical studies of some drugs don’t accurately reflect the populations that need them.

Case in Point: A Food and Drug Administration advisory panel recommended that the agency not approve Gilead’s HIV prevention drug Descovy for use by women because only men and transgender women were part of the clinical trials. The FDA could still clear the drug for women, but a debate on it highlights ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.